| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 403 | 2021 |
| Bevacizumab, bleeding, thrombosis, and warfarin S Kilickap, H Abali, I Celik Journal of clinical oncology: official journal of the American Society of …, 2003 | 213 | 2003 |
| Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of … X Pivot, J Gligorov, V Müller, G Curigliano, A Knoop, S Verma, V Jenkins, ... Annals of oncology 25 (10), 1979-1987, 2014 | 180 | 2014 |
| Association of the ABCB1 3435C>T polymorphism with antiemetic efficacy of 5‐hydroxytryptamine type 3 antagonists MO Babaoglu, B Bayar, AS Aynacioglu, R Kerb, H Abali, I Celik, A Bozkurt Clinical Pharmacology & Therapeutics 78 (6), 619-626, 2005 | 92 | 2005 |
| Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists H Abali, IH Güllü, H Engin, IC Haznedaroğlu, M Erman, G Tekuzman Medical hypotheses 59 (3), 344-348, 2002 | 82 | 2002 |
| Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience H Bekoz, M Ozbalak, N Karadurmus, S Paydas, A Turker, T Toptas, ... Annals of Hematology 99, 2565-2576, 2020 | 80 | 2020 |
| Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory … H Abalı, Y Ürün, B Öksüzoğlu, B Budakoğlu, N Yıldırım, T Güler, G Özet, ... Cancer investigation 26 (4), 401-406, 2008 | 70 | 2008 |
| Accelerated hepatitis C virus replication with rituximab treatment in a non‐Hodgkin's lymphoma patient S Aksoy, H Abali, S Kilickap, M Erman, A Kars Clinical & Laboratory Haematology 28 (3), 211-214, 2006 | 68 | 2006 |
| Disclosure of cancer diagnosis to patients and their relatives in Turkey: views of accompanying persons and influential factors in reaching those views B Öksüzoğrlu, H Abalı, M Bakar, N Yıldıirıim, N Zengin Tumori Journal 92 (1), 62-66, 2006 | 58 | 2006 |
| Circulating and local bone marrow renin-angiotensin system in leukemic hematopoiesis: preliminary evidences H Abali, IC Haznedaroglu, H Goker, I Celik, D Özatlı, Z Koray, M Caglar Hematology 7 (2), 75-82, 2002 | 52 | 2002 |
| Metastasis to the breast from nonmammarian solid neoplasms: a report of five cases B Öksüzoğlu, H Abalı, N Güler, E Baltalı, Y Özışık Medical Oncology 20, 295-300, 2003 | 45 | 2003 |
| Metastatic granular cell tumor: a case report and review of the literature S Aksoy, H Abali, S Kilickap, H Harputluoglu, M Erman Acta Oncologica 45 (1), 91-94, 2006 | 43 | 2006 |
| Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? M Erman, H Abali, B Oran, IC Haznedaroglu, H Canpinar, S Kirazli, I Celik Annals of oncology 15 (11), 1622-1626, 2004 | 43 | 2004 |
| Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation U Dişel, S Öztuzcu, AA Beşen, C Karadeniz, F Köse, AT Sümbül, A Sezer, ... Lung Cancer 71 (1), 109-112, 2011 | 36 | 2011 |
| It appears to be safe to start chemotherapy on the day of implantation through subcutaneous venous port catheters in inpatient setting NY Özdemir, H Abalı, B Öksüzoğlu, B Budakoğlu, İ Akmangit, N Zengin Supportive care in cancer 17, 399-403, 2009 | 36 | 2009 |
| Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost H Abali, I Celik Cancer investigation 25 (3), 135-139, 2007 | 33 | 2007 |
| Acute infusion reactions to chemotherapeutic drugs: a single institute experience S Muallaoglu, U Disel, H Mertsoylu, A Besen, C Karadeniz, AT Sumbul, ... J BUON 18 (1), 261-267, 2013 | 31 | 2013 |
| The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma NY Özdemir, H Abalı, B Öksüzoğlu, B Budakoglu, D Uncu, T Güler, ... Medical Oncology 27, 680-684, 2010 | 31 | 2010 |
| Effect of port-care frequency on venous port catheter-related complications in cancer patients H Odabas, NY Ozdemir, I Ziraman, S Aksoy, H Abali, B Oksuzoglu, M Isik, ... International journal of clinical oncology 19, 761-766, 2014 | 30 | 2014 |
| Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel AT Sümbül, A Sezer, H Abalı, F Köse, I Gültepe, H Mertsoylu, ... International urology and nephrology 46, 1531-1535, 2014 | 28 | 2014 |
